Insiders at Abbott Laboratories (ABT) sold $46m of stock on August 25, 2026, disclosed to the SEC on August 27, 2026. The largest was Ford Robert B, Chairman and CEO, at $46m. The stock closed at $116.13 that day, down 0.5%.
Across twelve months the stock has traded between $82.56 and $136.62, and today leaves it 62% up that band — neither end of it. The peak was September 22, 2025 (241 sessions ago), the floor May 11, 2026 (76 sessions ago).
The stock is up 3.1% over five sessions, up 12.7% over a month, down 12.2% over the year. The week and the year point in opposite directions. It closed above its thirty-day average price by 9.4%.
Intraday the stock covered 1.4%, in line with its 2.3% thirty-session norm, so the move arrived without unusual swings. The close finished mid-range, 69% up it.
Worth $185bn, the company sits 9 of 128 by size within healthcare. The sector as a whole finished +0.3%, leaning the other way.
From an open of $115.83 the price ranged down to $115.04 and up to $116.61 before closing on $116.13. That is 40.7% above the year's $82.56 floor and 15.0% under its $136.62 ceiling.
Turnover of $871m compares with $1.2bn on an average session for this stock. Against the year, today ranks between the +10.7% best and the -10.0% worst day.
Recent form leans positive: 21 of the last thirty sessions closed up against 7 down. Its strongest single day in the past year was +10.7% on July 16, 2026, its weakest -10.0% on January 22, 2026.
Its size-neighbours in the sector did not follow — AstraZeneca (AZN) +1.8% and Gilead Sciences (GILD) +1.4% — which argues for something particular to this company. ABT placed 96th of 986 on money traded.
This text was generated automatically from the closing data. It contains no forecasts and no investment advice — only what the numbers say. Do your own research.